Summer 2013 | Contemporary Oncology®

Novel Proteasome Inhibitors for Multiple Myeloma

October 17, 2013

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors

October 11, 2013

For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.